

**Supplementary Table 6.** Multivariable Cox regression analysis between atherogenic indices and kidney outcomes in individuals with CKD (baseline eGFR of <60 mL/min/1.73 m<sup>2</sup>)

| Atherogenic indices              | Model 1          |         | Model 2          |         | Model 3          |         |
|----------------------------------|------------------|---------|------------------|---------|------------------|---------|
|                                  | HR (95% CI)      | p-value | HR (95% CI)      | p-value | HR (95% CI)      | p-value |
| AIP per 1.0 increase             | 1.60 (1.07–2.39) | 0.02    | 1.59 (1.06–2.39) | 0.03    | 1.55 (1.01–2.37) | 0.04    |
| Q1                               | (Reference)      |         | (Reference)      |         | (Reference)      |         |
| Q2                               | 1.07 (0.79–1.43) | 0.67    | 1.07 (0.80–1.44) | 0.66    | 1.07 (0.79–1.44) | 0.68    |
| Q3                               | 1.04 (0.77–1.40) | 0.82    | 1.03 (0.77–1.40) | 0.83    | 1.06 (0.78–1.44) | 0.71    |
| Q4                               | 1.35 (1.02–1.80) | 0.03    | 1.35 (1.01–1.79) | 0.04    | 1.30 (1.08–1.52) | 0.03    |
| TC/HDL-C per 1.0 increase        | 1.05 (0.97–1.14) | 0.28    | 1.04 (0.96–1.13) | 0.31    | 1.03 (0.95–1.12) | 0.42    |
| Q1                               | (Reference)      |         | (Reference)      |         | (Reference)      |         |
| Q2                               | 0.90 (0.67–1.21) | 0.49    | 0.90 (0.67–1.21) | 0.50    | 1.05 (0.77–1.41) | 0.77    |
| Q3                               | 1.03 (0.77–1.37) | 0.86    | 1.03 (0.77–1.37) | 0.86    | 1.13 (0.85–1.52) | 0.41    |
| Q4                               | 0.96 (0.71–1.29) | 0.77    | 0.95 (0.71–1.28) | 0.73    | 0.97 (0.72–1.31) | 0.84    |
| LDL-C/HDL-C per 1.0 increase     | 0.97 (0.87–1.09) | 0.64    | 0.97 (0.87–1.08) | 0.59    | 0.97 (0.87–1.08) | 0.58    |
| Q1                               | (Reference)      |         | (Reference)      |         | (Reference)      |         |
| Q2                               | 0.95 (0.71–1.25) | 0.69    | 0.94 (0.71–1.25) | 0.67    | 1.02 (0.77–1.36) | 0.89    |
| Q3                               | 0.77 (0.58–1.04) | 0.09    | 0.77 (0.57–1.04) | 0.08    | 0.85 (0.63–1.15) | 0.29    |
| Q4                               | 0.84 (0.63–1.13) | 0.25    | 0.83 (0.62–1.12) | 0.23    | 0.83 (0.62–1.12) | 0.23    |
| Non-HDL-C/HDL-C per 1.0 increase | 1.05 (0.97–1.14) | 0.28    | 1.04 (0.96–1.13) | 0.31    | 1.03 (0.95–1.12) | 0.42    |
| Q1                               | (Reference)      |         | (Reference)      |         | (Reference)      |         |
| Q2                               | 0.90 (0.67–1.21) | 0.49    | 0.90 (0.67–1.21) | 0.50    | 1.05 (0.77–1.41) | 0.77    |
| Q3                               | 1.03 (0.77–1.37) | 0.86    | 1.03 (0.77–1.37) | 0.86    | 1.13 (0.85–1.52) | 0.41    |
| Q4                               | 0.96 (0.71–1.29) | 0.77    | 0.95 (0.71–1.28) | 0.73    | 0.97 (0.72–1.31) | 0.84    |

Model 1: unadjusted model; model 2: adjusted for age and sex; model 3: adjusted for age, sex, smoking, and alcohol status, body mass index, systolic blood pressure, hemoglobin, eGFR rate (Chronic Kidney Disease-Epidemiology Collaboration equation), use of lipid-lowering agents, past histories of hypertension, diabetes mellitus, coronary artery disease, cerebral infarction, dyslipidemia, and fatty liver.

AIP, atherogenic index of plasma; CI, confidence interval; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; HR, hazard ratio; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol.